Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohnʼs Disease: 2047

Published on Oct 1, 2018in The American Journal of Gastroenterology10.171
· DOI :10.14309/00000434-201810001-02047
Noa Krugliak Cleveland9
Estimated H-index: 9
,
Alexandra Masching1
Estimated H-index: 1
,
David T. Rubin91
Estimated H-index: 91
Source
Abstract
📖 Papers frequently viewed together
2 Citations
3 Citations
References0
Newest
Cited By2
Newest
#1Sheena Crosby (Mayo Clinic)H-Index: 1
#2Michael J Schuh (Mayo Clinic)H-Index: 3
Last. Francis A Farraye (Mayo Clinic)H-Index: 6
view all 3 authors...
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Gerben FerwerdaH-Index: 30
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 4 authors...
Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present three patients with therapy-refractory Crohn's disease, who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.
1 CitationsSource